"Medicube's Global Expansion Drives a 2x Revenue, 3x Profit Jump"
Source: 사업보고서 (2025.12) — Filed 2026.03.23 with DART | Separate (Standalone) Financial Statements | Unit: KRW millions
The APR financial analysis shows that FY2025 standalone revenue reached ₩1.53 trillion, up 111.4% from ₩723.0 billion in the prior year, while operating profit surged 199.1% to ₩354.1 billion and net income rose 170.7% to ₩289.9 billion. The core growth drivers were the top-line expansion from the Medicube brand's penetration into overseas channels such as North America and Japan, together with the fixed-cost leverage effect, which lifted the operating margin from 16.4% to 23.2%, an improvement of 6.8 percentage points. However, the most notable risk is the expansion of the working-capital burden, with trade receivables building up by an additional ₩73,847 million and inventories by an additional ₩62,315 million.
Key Financial Highlights
| Item | Prior (₩M) | Current (₩M) | YoY |
|---|---|---|---|
| Revenue | 723,001 | 1,528,296 | ▲111.4% |
| Operating Income | 118,398 | 354,122 | ▲199.1% |
| Op. Margin | 16.4% | 23.2% | +6.8pp |
| Net Income | 107,095 | 289,939 | ▲170.7% |
| Net Margin | 14.8% | 19.0% | +4.2pp |
| Operating Cash Flow | 22,098 | 295,429 | ▲1,236.9% |
| Free Cash Flow (FCF) | 8,311 | 287,910 | — |
Operating cash flow soared 1,236.9%, from ₩22,098 million to ₩295,429 million, normalizing free cash flow generation. On this basis, the company absorbed a net outflow of ₩178,629 million from financing activities (debt repayments and dividends), and the year-end cash balance recovered to ₩66,150 million.
1. Revenue and Profitability
| Item | Prior (₩M) | Current (₩M) | YoY |
|---|---|---|---|
| Revenue | 723,001 | 1,528,296 | ▲111.4% |
| Operating Income | 118,398 | 354,122 | ▲199.1% |
| Net Income | 107,095 | 289,939 | ▲170.7% |
| Op. Margin | 16.4% | 23.2% | +6.8pp |
| Net Margin | 14.8% | 19.0% | +4.2pp |
The operating margin rose 6.8 percentage points, from 16.4% in the prior year to 23.2% in the current period. The primary driver was that revenue growth (+111.4%) outpaced cost-of-sales growth (+101.7%), pushing the cost-of-sales ratio down 1.2 percentage points from 25.7% to 24.5%; the secondary driver was the full-fledged emergence of SG&A leverage, as the increase in cost of sales (₩189,051 million) amounted to only 23.5% of the revenue increase (₩805,295 million).
The net margin also improved by 4.2 percentage points, from 14.8% to 19.0%, but net-income growth (+170.7%) lagged operating-profit growth (+199.1%) by 28.4 percentage points. The direct cause was the sharp rise in total financial costs, which increased by ₩17,313 million (+126.6%), from ₩13,677 million to ₩30,990 million, expanding their share of revenue from 1.9% to 2.0%. The increase reflects a mix of pure interest expense, foreign-exchange losses, and financial-instrument valuation losses.
2. Cost Structure
| Cost Item | Prior (₩M) | Prior % | Current (₩M) | Curr % | YoY |
|---|---|---|---|---|---|
| COGS | 185,967 | 25.7% | 375,018 | 24.5% | ▲101.7% |
| Financial Costs | 13,677 | 1.9% | 30,990 | 2.0% | ▲126.6% |
- The degree of operating leverage (DOL) is 1.79, placing the company in the mid-leverage zone, where a 1% increase in revenue produces a 1.79% increase in operating profit.
- Cost-of-sales growth of 101.7% trailed revenue growth of 111.4% by 9.7 percentage points, lowering the cost-of-sales ratio from 25.7% to 24.5%. This reflects an expansion of higher-priced D2C and overseas direct-sales channels.
- The share of remaining costs (SG&A plus other operating expenses) declined by 5.6 percentage points, from 57.9% to 52.3%, demonstrating that fixed-cost leverage was the core driver of margin improvement.
3. Balance Sheet
3-1. Assets
| Item | Prior (₩M) | Current (₩M) | YoY |
|---|---|---|---|
| Cash & Equivalents | 38,755 | 66,150 | ▲70.7% |
| Trade Receivables | 85,052 | 158,899 | ▲86.8% |
| Inventories | 100,933 | 163,248 | ▲61.7% |
| Property & Equipment | 16,596 | 19,435 | ▲17.1% |
| Intangible Assets | 5,747 | 7,169 | ▲24.7% |
| Total Assets | 528,799 | 734,298 | ▲38.9% |
Total assets grew 38.9%, from ₩528,799 million to ₩734,298 million. Trade receivables rose 86.8% and inventories rose 61.7%, making working-capital items the central driver. PP&E grew only 17.1%, with FY2025 CapEx of ₩7,519 million, down 45.5% from ₩13,788 million in the prior year — indicating conservative, maintenance-focused investment rather than large-scale capacity expansion.
3-2. Liabilities
| Item | Prior (₩M) | Current (₩M) | YoY |
|---|---|---|---|
| Current Liabilities | 122,070 | 213,934 | ▲75.3% |
| Non-current Liabilities | 82,178 | 73,251 | ▼10.9% |
| Total Liabilities | 204,248 | 287,185 | ▲40.6% |
| Lease Liabilities | 16,608 | 20,511 | ▲23.5% |
3-3. Equity
| Item | Prior (₩M) | Current (₩M) | YoY |
|---|---|---|---|
| Common Stock | 3,813 | 3,893 | ▲2.1% |
| Retained Earnings | 230,058 | 428,494 | ▲86.3% |
| Total Equity | 324,551 | 447,114 | ▲37.8% |
Retained earnings increased on a net basis by ₩198,436 million, from ₩230,058 million to ₩428,494 million, while net income was ₩289,939 million. The difference of ₩91,503 million was used for shareholder returns such as dividend payments and treasury-stock buybacks, consistent with the financing cash flow of -₩178,629 million.
4. Cash Flow Analysis
| Item | 2Y Prior (₩M) | Prior (₩M) | Current (₩M) |
|---|---|---|---|
| Operating Cash Flow | 106,557 | 22,098 | 295,429 |
| CapEx | 3,657 | 13,788 | 7,519 |
| Investing Cash Flow | -26,013 | -96,654 | -88,474 |
| Financing Cash Flow | -13,372 | -2,688 | -178,629 |
| Income Tax Paid | 17,497 | 28,968 | 22,741 |
| Free Cash Flow (FCF) | — | 8,311 | 287,910 |
Operating cash flow rose by ₩273,331 million (+1,236.9%), from ₩22,098 million to ₩295,429 million, fully recovering from the temporary slowdown of the prior year. In the prior year, the buildup of trade receivables and inventories sharply eroded operating cash flow; in FY2025, however, the scale of profit itself nearly tripled, fully absorbing the increase in working capital.
Financing cash flow swung from -₩2,688 million to -₩178,629 million, an additional outflow of ₩175,941 million, as debt repayment and dividend payments proceeded simultaneously. Operating cash flow of ₩295,429 million more than fully covered them, and year-end cash actually grew 70.7% to ₩66,150 million.
5. Key Financial Ratios
| Ratio | 2Y Prior | Prior | Current |
|---|---|---|---|
| Operating Margin | 20.0% | 16.4% | 23.2% |
| Net Margin | 15.6% | 14.8% | 19.0% |
| ROE | 41.3% | 33.0% | 64.8% |
| ROA | 29.7% | 20.3% | 39.5% |
| Current Ratio | — | 2.21× | 2.44× |
| D/E Ratio | 0.28× | 0.39× | 0.39× |
| Financial Cost Coverage | — | 8.66× | 11.43× |
ROA jumped 19.2 percentage points, from 20.3% to 39.5%, marking the company's all-time-high profitability. ROE also expanded sharply, from 33.0% to 64.8%. The operating margin traced a "V-shaped recovery" of 20.0% → 16.4% → 23.2%, while the net margin trended upward, 15.6% → 14.8% → 19.0%. The financial-cost coverage ratio improved from 8.66× to 11.43×, leaving ample debt-service capacity.
6. Key Implications and Outlook
Growth Catalysts
1. Acceleration of the Medicube brand's global penetration
Top-line growth of ₩1.53 trillion in revenue, up 111.4% year on year, reflects the full-fledged emergence of a single brand's channel expansion across North America, Japan, and Southeast Asia. Combined with global demand expansion in K-beauty devices and skincare categories, the decline in the cost-of-sales ratio from 25.7% to 24.5% indicates that the unit-price structure improved as the share of overseas D2C channels expanded.
2. Full-fledged emergence of fixed-cost leverage
As the DOL of 1.79× confirms, doubled revenue translated into tripled operating profit, lifting the operating margin by 6.8 percentage points. Despite CapEx falling 45.5%, the doubling of the top line shows that the company has the capacity to expand revenue through utilization rates and channel efficiency without additional capacity investment.
3. Normalization of cash generation and capacity for shareholder returns
Operating cash flow grew more than 13×, and even with ₩178,629 million flowing out through financing activities, year-end cash rose 70.7%. The financial strength represented by an ROA of 39.5% (ROE 64.8%) and a financial-cost coverage ratio of 11.43× supports future capacity for share buybacks and dividend expansion.
Risks
1. Working-capital concentration alongside top-line growth
Trade receivables grew by ₩73,847 million and inventories by ₩62,315 million, outpacing the speed of revenue growth. While the current ratio actually rose from 2.21× to 2.44×, the buildup of receivables and inventories remains a risk: if revenue growth slows, any inventory write-downs or bad-debt incidents would transmit an immediate shock to operating profit.
2. Net-income erosion from doubled financial costs
Total financial costs rose by an additional ₩17,313 million (+126.6%), from ₩13,677 million to ₩30,990 million, creating the 28.4-percentage-point gap between the operating-profit growth rate (+199.1%) and the net-income growth rate (+170.7%). Further FX volatility or any rise in benchmark interest rates would cause additional margin erosion.
3. Deepening dependence on a single brand and overseas revenue
The doubling of revenue is in effect concentrated on a single Medicube axis, and exposure to FX and tariff volatility of overseas channels has increased. Intensifying competition in K-beauty devices in the U.S. and Japanese markets could directly shake the downside stability of the 24.5% cost-of-sales ratio.
Overall Assessment
In FY2025, APR delivered a triple jump — revenue +111.4%, operating profit +199.1%, and ROA 39.5% — establishing itself as a global leader in the K-beauty device category. As operating cash flow of ₩295,429 million and a financial-cost coverage ratio of 11.43× show, both earnings quality and financial stability improved. However, the doubling of total financial costs and the rapid buildup of trade receivables and inventories indicate that working-capital exposure and FX/financial burdens are accumulating beneath the surface of top-line growth.
The key points to watch over the next 12 months are whether trade-receivable and inventory turnover normalize, and the results of new category and regional expansion to diversify away from single-brand dependence.
Disclaimer: This report is intended to provide information based on DART disclosure data and does not constitute an investment recommendation.
